SANA BIOTECHNOLOGY INC

SANANASDAQ

🏆 #2180 by market capUS Equity

$3.75▼ $0.05 (−1.32%)

Live

1h▼ 0.5%

24h▼ 1.3%

7d▲ 6.4%

14d▲ 17.6%

30d▲ 2.7%

1y▲ 20.4%

🏦Market Cap

$1.04B

Small Cap

📈Revenue Growth (YoY)

+0.0%

Slowing

📊Gross Margin

0.0%

Thin

💵FCF Margin

0.0%

Thin

⚖️P/S Ratio

0.0x

Cheap

Otter Score

Weak

Trading Snapshot

Day Range: $3.71 – $3.82
52-Week Range: $2.61 – $6.55
Volume: $2.99B
Avg Volume: $2.31B
Shares Outstanding: 278.3M
Next Earnings: Oct 12, 2026

Fundamentals Snapshot

Annual Revenue: $67M
Last Q Revenue: $17M
P/E Ratio: -5.0
P/S Ratio: 0.0x
EPS (TTM): $-0.72
Dividend Yield: 0.00%

Why Investors Own SANA

✓High-growth profile — revenue up +28.6% YoY with expanding US Equity exposure.
✓Healthy economics — 59% gross margin and 13% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$67M▲ +33.3% YoY

Gross Margin (TTM)

59.1%▲ +1.6% YoY

Operating Income (TTM)

$17M▲ +33.3% YoY

Free Cash Flow (TTM)

$9M▲ +33.3% YoY

About SANA BIOTECHNOLOGY INC

Sana Biotechnology, Inc. is a biotechnology firm focused on creating treatments using engineered cells. The company develops advanced ex vivo and in vivo cell engineering platforms to address a range of conditions with significant unmet medical needs, including various cancers, diabetes, central nervous system disorders, cardiovascular diseases, and genetic illnesses. Its portfolio of drug candidates includes SG295 and SG242, which are designed to target CD19+ cancer cells involved in non-Hodgkin Lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia. For multiple myeloma, Sana is progressing SG221, SG239, and SC255. Other pipeline assets include SG328 for ornithine transcarbamylase deficiency, and SG418 for sickle cell disease and beta-thalassemia. Additionally, the company is advancing SC291, a CD19 allogeneic T cell therapy, SC451 for type I diabetes mellitus, and SC379 for secondary progressive multiple sclerosis, Pelizaeus-Merzbacher disease, and Huntington's disease. Founded in 2018 as FD Therapeutics, Inc., the company adopted its current name, Sana Biotechnology, Inc., in September 2018 and is based in Seattle, Washington.

🦦